Reve Technologies, Inc. (BSSP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2014 | 181.48 Thousand USD | 128.33% |
| 2013 | 79.48 Thousand USD | 46.03% |
| 2012 | 54.42 Thousand USD | -38.48% |
| 2011 | 88.47 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2015 Q1 | 109.8 Thousand USD | 91.31% |
| 2015 Q2 | 201.97 Thousand USD | 83.94% |
| 2015 Q3 | 29.77 Thousand USD | -85.26% |
| 2014 Q2 | 46.21 Thousand USD | 40.71% |
| 2014 Q4 | 57.39 Thousand USD | 27.45% |
| 2014 Q3 | 45.03 Thousand USD | -2.56% |
| 2014 FY | 181.48 Thousand USD | 128.33% |
| 2014 Q1 | 32.84 Thousand USD | 18.4% |
| 2013 FY | 79.48 Thousand USD | 46.03% |
| 2013 Q4 | 27.74 Thousand USD | -9.72% |
| 2013 Q2 | 16.86 Thousand USD | 306.78% |
| 2013 Q1 | 4147.00 USD | -61.35% |
| 2013 Q3 | 30.72 Thousand USD | 82.14% |
| 2012 FY | 54.42 Thousand USD | -38.48% |
| 2012 Q3 | 9274.00 USD | 5.69% |
| 2012 Q2 | 8775.00 USD | -65.79% |
| 2012 Q1 | 25.65 Thousand USD | 224.64% |
| 2012 Q4 | 10.72 Thousand USD | 15.69% |
| 2011 Q2 | 9069.00 USD | 84.22% |
| 2011 Q1 | 4923.00 USD | 0.0% |
| 2011 FY | 88.47 Thousand USD | 0.0% |
| 2011 Q3 | 66.58 Thousand USD | 634.16% |
| 2011 Q4 | 7901.00 USD | -88.13% |
| 2010 Q3 | 1038.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 86.41% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 96.401% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.386% |
| Nascent Biotech, Inc. | 2.22 Million USD | 91.861% |
| Rebus Holdings, Inc. | 664 Thousand USD | 72.668% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.513% |
| Qrons Inc. | 643.67 Thousand USD | 71.805% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 53.414% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.684% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 56.319% |
| Skye Bioscience, Inc. | 13.54 Million USD | 98.66% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.791% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 96.31% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 30.658% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.788% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 93.777% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 87.916% |
| Mesoblast Limited | 5.9 Million USD | 96.925% |
| Marizyme, Inc. | 19.23 Million USD | 99.057% |
| Genus plc | 147.7 Million USD | 99.877% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 97.933% |
| Pharming Group N.V. | 225.49 Million USD | 99.92% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 91.141% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 86.472% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 97.824% |
| ContraFect Corporation | 56.88 Million USD | 99.681% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 95.883% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 87.727% |
| IMV Inc. | 37.7 Million USD | 99.519% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 93.496% |
| MultiCell Technologies, Inc. | 567.42 USD | -31884.244% |
| ONE Bio Corp. | 6.44 Million USD | 97.184% |
| Accustem Sciences Inc. | 3.74 Million USD | 95.156% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.789% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 65.884% |
| Q BioMed Inc. | 3.43 Million USD | 94.719% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.266% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 93.093% |
| Biomind Labs Inc. | 994.18 Thousand USD | 81.745% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.817% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 89.686% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 97.299% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 90.266% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 825.94% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 98.866% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 90.11% |
| GB Sciences, Inc. | 1.42 Million USD | 87.224% |
| Alpha Cognition Inc. | 9.7 Million USD | 98.13% |
| HST Global, Inc. | 140.9 Thousand USD | -28.798% |
| CSL Limited | 3.44 Billion USD | 99.995% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 83.867% |
| Halberd Corporation | 74.84 Thousand USD | -142.491% |
| Enzolytics Inc. | 2.17 Million USD | 91.673% |
| Agentix Corp. | 1.37 Million USD | 86.77% |
| Resverlogix Corp. | 12.71 Million USD | 98.572% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 95.029% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.988% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 82.616% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 92.454% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 88.509% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 94.67% |
| AVAX Technologies, Inc. | 7.31 Million USD | 97.517% |
| Zenith Capital Corp. | 8.94 Million USD | 97.971% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.978% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -941.76% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 92.608% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -5.817% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 90.552% |
| Kadimastem Ltd | 2.41 Million USD | 92.47% |
| Helix BioMedix, Inc. | 1.97 Million USD | 90.797% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 98.33% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.21% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| LadRx Corporation | 3.81 Million USD | 95.239% |
| Cell Source, Inc. | 4.32 Million USD | 95.804% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 80.348% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 80.348% |
| NovAccess Global Inc. | 2.46 Million USD | 92.643% |
| Affymax, Inc. | 39.38 Million USD | 99.539% |
| Itoco Inc. | 919.14 Thousand USD | 80.255% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 95.718% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 83.782% |
| Mobile Lads Corp. | 554.54 Thousand USD | 67.273% |
| CytoDyn Inc. | 18.05 Million USD | 98.995% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -621.066% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 17.536% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 87.217% |
| SYBLEU INC | 160.87 Thousand USD | -12.81% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 90.008% |
| International Stem Cell Corporation | 5.27 Million USD | 96.557% |
| Bioxytran, Inc. | 3.82 Million USD | 95.249% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -244.753% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -792.125% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.5% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 88.783% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 75.336% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 94.166% |
| Neutra Corp. | 243.82 Thousand USD | 25.566% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 98.96% |
| PureTech Health plc | 144.59 Million USD | 99.874% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.114% |
| IXICO plc | 4.7 Million USD | 96.144% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 97.937% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.846% |
| CSL Limited | 3.89 Billion USD | 99.995% |
| Cellectis S.A. | 97.32 Million USD | 99.814% |